Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12624001421527
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
6/11/2024
Date registered
Help: Date registered
4/12/2024
Date last updated
Help: Date last updated
9/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
4/12/2024
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A Research Study Testing NGM120 in Pregnant Women with Severe Nausea and Vomiting (Hyperemesis Gravidarum)
Scientific title
A Phase 2 Randomized, Proof of Concept Study to Evaluate the Safety, Tolerability, and Efficacy of NGM120 in Pregnant Women with Severe Nausea and Vomiting (Hyperemesis Gravidarum)
Additional trial identifiers [1] 312798 0
120-HG-201
Universal Trial Number (UTN)
Trial acronym
EMERALD
Related trial records

Health condition
Health condition(s) studied:
Hyperemesis Gravidarum 334861 0
Condition category
Condition code
Reproductive Health and Childbirth 331417 331417 0 0
Antenatal care
Reproductive Health and Childbirth 331685 331685 0 0
Fetal medicine and complications of pregnancy
Reproductive Health and Childbirth 331686 331686 0 0
Other reproductive health and childbirth disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The study drug is NGM120, a humanized monoclonal antibody. A single dose (75 mg) will be administered subcutaneously (SC) by the study center staff on either Day 1 (the first day of Study Period 1, which runs from Day 1 through Day 7) or Day 8 (the first day of Study Period 2, which runs from Day 8 through Day 12) of the study, according to the treatment sequence assigned.
There is no wash out between administration of the first assigned treatment on Day 1 and administration of the second assigned treatment on Day 8.
Additionally, participants will continue anti-emetics, supportive care, or other treatments for HG as per local guidelines with no changes in HG medications and their doses from Day -3 to Day 12.
Intervention code [1] 329334 0
Treatment: Drugs
Description of the comparator or control
A single dose of placebo (a sterile solvent, the injection solution will be provided at a concentration of 0 mg/mL NGM120) will be administered subcutaneously on either Day 1 or Day 8 of the study, according to the treatment sequence assigned.
Supportive care and SOC will be administered as described above.
Control group
Placebo

Outcomes
Primary outcome [1] 339167 0
The safety and tolerability (assessed as a composite outcome) of NGM120 in addition to SOC and supportive care.
Timepoint [1] 339167 0
Study Days 1, 5, 8, and 12, every 6 weeks thereafter until birth, at birth, 14 days postpartum, and at early termination, if applicable.
Secondary outcome [1] 438869 0
Pregnancy-Unique Quantification of Emesis 24 (PUQE-24) scores
Timepoint [1] 438869 0
Baseline and Study Day 5.
Secondary outcome [2] 438870 0
HyperEmesis Level Prediction (HELP) scores
Timepoint [2] 438870 0
Baseline and Study Day 5.

Eligibility
Key inclusion criteria
1. Pregnant females with singleton pregnancy and gestational age of the fetus is 9+0 to 16+6 weeks
2. Severe nausea and vomiting with PUQE-24 greater than or equal to 12 at randomization (Day 1).
3. Agree to no medication changes to anti-emetics or other treatments for hyperemesis gravidarum (HG) per local guidelines with no changes in treatment or dosage from Study Day -3 through Study Day 12.
Minimum age
18 Years
Maximum age
45 Years
Sex
Females
Healthy volunteers
No
Key exclusion criteria
1. History of cyclic vomiting or gastroparesis which could contribute to the etiology of nausea and vomiting.
2. Prior health conditions (i.e., bowel obstruction, pancreatitis, or surgical adhesions in bowel) which could contribute to the etiology of nausea and vomiting.
3. Active HBV, HCV, or HIV infection as determined by positive viral load or antigenemia as per local standard of care. Participants cured of HCV infection prior to screening are eligible.
4. Pre-existing diagnosis of chronic kidney disease, uncontrolled diabetes (type 1 or 2), significant cardiac disease (including long QT syndrome) or epilepsy.
5. Elevated liver enzymes (alanine aminotransferase or aspartate aminotransferase greater than or equal to 3.0 times the upper limit of normal).
6. Known fetal chromosomal abnormalities.
7. Use of alcohol, illicit drugs, or nicotine during pregnancy.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All participants will be centrally assigned to randomized study treatment using an Interactive Web Response System.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
A randomization schedule was generated prior to the study by an unblinded statistician.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Crossover
Other design features
Phase
Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
6/12/2024
Actual
3/02/2025
Date of last participant enrolment
Anticipated
30/04/2026
Actual
10/04/2026
Date of last data collection
Anticipated
30/11/2026
Actual
Sample size
Target
31
Accrual to date
Final
31
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC
Recruitment hospital [1] 27122 0
Royal Brisbane & Womens Hospital - Herston
Recruitment hospital [2] 27123 0
GenesisCare - Mater Hospital - North Sydney
Recruitment hospital [3] 27124 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [4] 27125 0
Liverpool Hospital - Liverpool
Recruitment hospital [5] 27259 0
Lyell McEwin Hospital - Elizabeth Vale
Recruitment postcode(s) [1] 43200 0
4029 - Herston
Recruitment postcode(s) [2] 43201 0
2060 - North Sydney
Recruitment postcode(s) [3] 43202 0
3168 - Clayton
Recruitment postcode(s) [4] 43203 0
2170 - Liverpool
Recruitment postcode(s) [5] 43346 0
5112 - Elizabeth Vale
Recruitment outside Australia
Country [1] 26522 0
United Kingdom
State/province [1] 26522 0
Country [2] 28018 0
Philippines
State/province [2] 28018 0

Funding & Sponsors
Funding source category [1] 317231 0
Commercial sector/Industry
Name [1] 317231 0
NGM Biopharmaceuticals, Inc.
Country [1] 317231 0
United States of America
Primary sponsor type
Commercial sector/Industry
Name
NGM Biopharmaceuticals, Inc.
Address
Country
United States of America
Secondary sponsor category [1] 319511 0
None
Name [1] 319511 0
Address [1] 319511 0
Country [1] 319511 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 315968 0
Women's and Children's Health Network Human Research Ethics Committee
Ethics committee address [1] 315968 0
Ethics committee country [1] 315968 0
Australia
Date submitted for ethics approval [1] 315968 0
28/08/2024
Approval date [1] 315968 0
29/10/2024
Ethics approval number [1] 315968 0
Ethics committee name [2] 315969 0
North East – Tyne & Wear South
Ethics committee address [2] 315969 0
Ethics committee country [2] 315969 0
United Kingdom
Date submitted for ethics approval [2] 315969 0
23/08/2024
Approval date [2] 315969 0
Ethics approval number [2] 315969 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 136374 0
Prof Bill Hague
Address 136374 0
Robinson Research Institute of The University of Adelaide, 55 King William Road, North Adelaide, SA 5006
Country 136374 0
Australia
Phone 136374 0
+61 041 111 4575
Fax 136374 0
Email 136374 0
[email protected]
Contact person for public queries
Name 136375 0
NGM Study Director
Address 136375 0
NGM Biopharmaceuticals, Inc., 611 Gateway Blvd., Suite 540, South San Francisco, CA 94080 USA
Country 136375 0
United States of America
Phone 136375 0
+16507278800
Fax 136375 0
Email 136375 0
[email protected]
Contact person for scientific queries
Name 136376 0
NGM Study Director
Address 136376 0
NGM Biopharmaceuticals, Inc., 611 Gateway Blvd., Suite 540, South San Francisco, CA 94080 USA
Country 136376 0
United States of America
Phone 136376 0
+16507278800
Fax 136376 0
Email 136376 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.